Nelson Handal, MD
Child & Adolescent Psychiatry · Dothan, ALNPI 1154471548
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Corium, LLC at 44.3% of the total. Reporting peaked in 2023 at $25,917 and has fallen 84.7% since, to $3,970 in 2025. Among child & adolescent psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 566 payments — averaging $141.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$36K
- Idorsia Pharmaceuticals US Inc$10K
- Supernus Pharmaceuticals, Inc.$9K
- Shire North American Group Inc$6K
- Ironshore Pharmaceuticals Inc.$5K
- Neuronetics, Inc.$3K
- plus $11K from 24 others
Across 568 payments — averaging $4304.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$524K
- F. Hoffmann-la Roche AG$351K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$346K
- Sage Therapeutics, LLC$212K
- Genentech, Inc.$181K
- Janssen Research & Development, LLC$176K
- plus $654K from 15 others
What the payments were for
- Consulting fees$21,17026%
- Speaking & faculty fees$37,55547%
- Travel & lodging$7,62510%
- Food & beverage$10,95114%
- Education$920%
- Other$2,8094%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 70 | $35,546 |
| Idorsia Pharmaceuticals US Inc | 26 | $9,963 |
| Supernus Pharmaceuticals, Inc. | 18 | $9,301 |
| Shire North American Group Inc | 14 | $5,826 |
| Ironshore Pharmaceuticals Inc. | 32 | $5,360 |
| Neuronetics, Inc. | 7 | $3,014 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $2,519 |
| Roche Products Limited | 3 | $1,780 |
| Johnson & Johnson | 59 | $1,247 |
| AbbVie(2 entities) | 82 | $1,195 |
| Vanda Pharmaceuticals Inc. | 34 | $914 |
| Otsuka America Pharmaceutical, Inc. | 36 | $624 |
| Tris Pharma Inc | 30 | $572 |
| Almatica Pharma LLC | 26 | $506 |
| Alkermes, Inc. | 14 | $359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $250 |
| Axsome Therapeutics, Inc. | 12 | $225 |
| Neos Therapeutics, LP | 12 | $176 |
| Neurocrine Biosciences, Inc. | 8 | $172 |
| Eisai Inc. | 10 | $154 |
| Sunovion Pharmaceuticals Inc. | 8 | $108 |
| Teva Pharmaceuticals USA, Inc. | 6 | $96 |
| Genentech, Inc. | 2 | $80 |
| Lundbeck LLC | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Brainsway USA Inc | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$34,229
- QUVIVIQ$9,599
- QELBREE$6,225
- Jornay PM 20mg capsules (Bottle of 100)$4,763
- NEUROSTAR TMS THERAPY SYSTEM$2,809
- CAPLYTA$1,980
- Non-Covered Product$1,780
- LYBALVI$443
- Fanapt$232
- VRAYLAR$125
- SPRAVATO$121
- Dyanavel XR$118
- Quillivant$118
- Quillichew ER$118
- NEUROSTAR TMS THERAPY$107
How this compares
$80,202 in reported general payments places this provider in the 95th percentile of 40 child & adolescent psychiatry providers in Alabama.
See all child & adolescent psychiatry providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 42 | $61,889 |
| SpravatoEsketamine Hcl | 27 | $26,896 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,644 |
| LamictalLamotrigine | 20 | $13,043 |
| QuviviqDaridorexant Hcl | 25 | $12,089 |
| Lisdexamfetamine Dimesylate | 48 | $9,120 |
| Jornay PmMethylphenidate Hcl | 13 | $5,949 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 47 | $4,727 |
| Lurasidone Hcl | 27 | $4,237 |
| Asenapine Maleate | 11 | $3,454 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 39 | $3,129 |
| Aripiprazole | 53 | $2,662 |
| Dextroamphetamine Sulfate | 22 | $2,367 |
| Naltrexone Hcl | 15 | $2,243 |
| Trazodone Hcl | 90 | $1,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,195 | $61,88942 claims |
| Johnson & JohnsonSpravato | $1,247 | $26,89627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $250 | $13,64436 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $9,963 | $12,08925 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $5,360 | $5,94913 claims |
| Almatica Pharma LLCSertraline Hcl | $506 | $31142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 child & adolescent psychiatry providers in Alabama.
Other child & adolescent psychiatry in Dothan
- Jerlyn McCleodDothan$9K
- Artie NelsonBirmingham$32K
- Karen CallahanBirmingham$5K
- Curtis AdamsHuntsville$5K
- Casey LowreyBirmingham$4K
- Aparna VuppalaHuntsville$3K
- Richard SinclairMobile$2K
- John Broderick-CantwellDaphne$2K
- Christiana WilkinsOpelika$1K
- Elizabeth FergusonBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.